Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 4/20 | 0.38 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.38 |
| ▸ | PRKCH | P24723 | 5/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.36 |
| ▸ | PRKCB | P05771 | 2/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 11/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30913251 | 0.92 | PRKCH (0.37) | LATS1LATS2PRKCHPRKCQPRKCE | |
| SCHEMBL30913262 | 0.84 | LATS1 (0.38) | LATS1LATS2PRKCHPRKCQPRKCE | |
| SCHEMBL24379645 | 0.78 | PRKCH (0.37) | LATS1LATS2PRKCHPRKCQPRKCE | |
| SCHEMBL24379644 | 0.78 | PRKCH (0.37) | LATS1LATS2PRKCHPRKCQPRKCE | |
| SCHEMBL30913253 | 0.77 | LATS1 (0.34) | LATS1LATS2PRKCHPRKCQPRKCE | |
| SCHEMBL25857289 | 0.74 | LATS1 (0.41) | LATS1LATS2MAOA | |
| SCHEMBL29560059 | 0.71 | KDR (0.39) | PRKCHPRKCQPRKCEPRKCD | |
| SCHEMBL24379571 | 0.70 | KDR (0.37) | PRKCHPRKCQPRKCEPRKCDROCK2 | |
| SCHEMBL32660756 | 0.70 | KDR (0.37) | PRKCHPRKCQPRKCEPRKCDROCK2 | |
| SCHEMBL30913247 | 0.69 | TRPM8 (0.42) | LATS1LATS2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158396-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2024-05-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158396-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | LATS1 3683/4885LATS2 3294/4885PRKCH 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.